Background
==========

ERCP is one of the important procedures for diagnosis and treatment of several biliary and pancreatic conditions. However, ERCP can also cause acute pancreatitis and result in significant morbidity and mortality \[[@B1],[@B2]\]. Depending on the definition, it has been reported that incidence of post-ERCP pancreatitis (PEP) was 1% to 40% of cases, whereas post-operative hyperamylasemia can be up to 70% of cases \[[@B3]\]. Although most cases of PEP were mild, about 10% of them were severe pancreatitis \[[@B4]\], which could result in prolonged stay in hospitals and increase risk to patients\' life.

There were numerous attempts to minimize occurrence and severity of PEP. However most of them were disappointed. Prevention of PEP with calcitonin, aprotonin, nifedipine and glucagon did not show any decrease in post-ERCP hyperamylasemia or pancreatitis \[[@B5]-[@B8]\]. Moreover, a few studies with long-acting somatostatin analogue -- octreotide produced conflicting results \[[@B9]-[@B12]\]. Furthermore, a recent meta-analysis of all prospective randomized clinical trials (RCTs) of protease inhibitor -- gabexate mesilate concluded that gabexate mesilate cannot prevent the pancreatic injury after ERCP \[[@B13]\].

Corticosteroid is an anti-inflammatory hormone and is able to ameliorate injury response. It has been shown that corticosteroid is able to increase activity of C1-antiprotease inhibitor \[[@B14]\], decrease synthesis of phospholipase A2 \[[@B15]\], and suppress cellular and humoral responses. Since acute pancreatitis is a process of autodigestion characterized by release of activated pancreatic enzymes \[[@B16]\], corticosteroid may reduce inflammatory response during initial steps of autodigestive cascade. Therefore, one large retrospective and 7 prospective studies of corticosteroid in prophylaxis of PEP have been conducted recently \[[@B17]-[@B24]\]. However, these studies could not reach a clear conclusion about beneficial effects of corticosteroid on prophylaxis of PEP. Therefore, it will be necessary to conduct a meta-analysis of all available RCTs to reveal use of corticosteroid in prophylaxis of PEP.

Methods
=======

Selection criteria
------------------

We searched different databases, which included the Cochrane Controlled Trials Register on The Cochrane Library Issue 2, 2007, MEDLINE (January, 1966 -- June, 2007), EMBASE.com (January, 1966 -- June, 2007) and the China Biological Medicine Datadase (CBMdisc) (January, 1978 -- June, 2007) by the terms of *pancreatitis*, *ERCP*, *prevent*\*, *corticosteroid*, *prednisone*, *PEP*. The reference lists of pertinent reviews and retrieved articles had been checked for additional study identification.

In the meta-analysis, the following inclusive selection criteria were set and reviewed by two independent investigators: (1) each trial should be a prospective randomized controlled clinical trial, (2) the age of patient population should be over 18 years, (3) the patients were scheduled to undergo ERCP and/or endoscopic sphincterotomy, (4) randomized comparisons of corticosteroid versus placebo should be included regardless of initial time of treatment, treatment duration, dose and administration route of drug, (5) co-interventions (including treatment of complications) were allowed if administered equally to all intervention groups. The following exclusive selection criteria were set: (1) quasi-randomized trials and non-randomized studies, (2) active acute pancreatitis, (3) difference of co-interventions between intervention arms, (4) repetitive reports (if more than one version of the same study was retrieved, only the most recent one was used).

A total of 15 clinical trials and reports has been identified and only seven trials \[[@B18]-[@B24]\] were qualified by our selection criteria (Figure [1](#F1){ref-type="fig"}). Four out of seven studies included patients submitted only to diagnostic ERCP and three to diagnostic and therapeutic ERCP. All of the studies adopted the PEP diagnostic criteria that Cotton et al. \[[@B3]\] proposed in 1991 and a severe PEP was reported in five studies. Five out of seven RCTs were adequate in the allocation concealment judgment and two were unclear. The studies were independently evaluated by two of us with five outcomes, which included three primary outcomes (PEP, severe PEP and case-fatality ratio of PEP) and two secondary outcomes (post-ERCP hyperamylasemia and abdominal pain). Discrepancies in the evaluation of some studies were resolved through discussion between the reviewers. Main features of the trials included in meta-analysis are shown in Table [1](#T1){ref-type="table"}.
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###### 

Randomized controlled trials on the use of corticosteroid for the prevention of pancreatic injury after ERCP

  Author and publication year   Setting                     Jadad score   Sample size   Type of corticosteroid administration   Dosage (mg)   Duration
  ----------------------------- --------------------------- ------------- ------------- --------------------------------------- ------------- ----------------------------------
  Budzynska, 1997               Poland single centre        1             184           Prednisone, orally                      40            15 hours and 3 hours before ERCP
  Dumot, 1998                   United States multicentre   4             255           Methylprednisolone, intravenous bolus   125           15 to 30 minutes before ERCP
  De Palma, 1999                Italy single centre         5             529           Hydrocortisone, intravenous infusion    100           Immediately before ERCP
  Budzynska, 2001               Poland single centre        2             201           Prednisone, orally                      40            15 hours and 3 hours before ERCP
  Manolakopoulos, 2002          Greece multicentre          5             228           Hydrocortisone, intravenous infusion    100           30 minutes before ERCP
  Sherman, 2003                 United States multicentre   4             1115          Prednisone, orally                      40            15 hours and 3 hours before ERCP
  Kwanngern, 2005               Thailand single centre      4             120           Hydrocortisone, intravenous infusion    100           1 hour before ERCP

Assessment of study quality
---------------------------

Quality of included reports was scored using the Jadad composite scale \[[@B25]\], which assesses descriptions of randomization, blinding, and dropouts (withdrawals) in reports \[[@B26]\]. The quality scale ranges from 0 to 5 points with a low-quality report of score at 2 or less and a high-quality report of score at least 3 \[[@B27]\].

Statistical analysis
--------------------

The meta-analysis was carried out by a biostatistician (Jianling Bai) according to the Cochrane Reviewers\' Handbook recommended by The Cochrane Collaboration. Pooled odds ratio (OR) was calculated using the general inverse variance (IV) fixed-effect model. The heterogeneity between studies was examined by DL Q statistic \[[@B28]\]. If results were heterogeneous (p \< 0.05), a random-effects model was employed using the DerSimonian and Laird (DL) methods. For studies in which the constructed 2×2 tables contained cells with zero events, a standard correction factor of 0.5 was added to each cell. Pooled OR was presented as standard plots with 95 percent confidence intervals (CI). Publication bias was measured by Begg and Mazumdar\'s proposed adjusted rank correlation test \[[@B29]\] and Egger\'s linear regression approach \[[@B30]\], and was shown as a funnel plot. Sensitivity-analysis was also performed to assess the reliability of meta-analysis. The statistical package RevMan version 4.2 (provided by The Cochrane Collaboration, Oxford, England) was used for statistical analysis.

Results
=======

Primary outcome
---------------

In this report, we considered PEP as the primary outcome which was divided into general PEP and severe PEP. The report of general PEP was noticed in all seven RCTs \[[@B18]-[@B24]\]. These trials included 2632 patients with 299 patients suffering from PEP. Among PEP-suffering patients, 157 (12.0%) patients were treated with corticosteroid whereas 142 (10.8%) patients were treated with placebo. There was no significant heterogeneity among these studies (χ^2^= 8.56, 6 degrees of freedom, p = 0.20). However, analysis by a fixed-effects model indicated an IV fixed-effect pooled OR = 1.13 \[(95 percent CI 0.89 to 1.44); p = 0.32\] with no significant association between the use of corticosteroid and the reduction of PEP (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). When stratified by setting, there was no significant reduction of PEP in either single centre studies (IV fixed-effect pooled OR = 1.04 \[(95 percent CI 0.66 to 1.64); p = 0.87\]) or multicentre studies (IV fixed-effect pooled OR = 1.17 \[(95 percent CI 0.88 to 1.56); p = 0.29\]) (Table [3](#T3){ref-type="table"}). There was also no significant heterogeneity in either single centre studies (χ^2^= 4.75, 3 degrees of freedom, p = 0.19) or multicentre studies (χ^2^= 3.84, 2 degrees of freedom, p = 0.15). Moreover, when studies were stratified by Jadad score, there was no significant reduction in PEP in Jadad score at 2 or less (IV fixed-effect pooled OR = 1.31 \[(95 percent CI 0.70 to 2.46); p = 0.39) or Jadad score at least 3 (IV fixed-effect pooled OR = 1.10 \[(95 percent CI 0.85 to 1.43); p = 0.47). There was no significant heterogeneity in either Jadad score at 2 or less (χ^2^= 0.28, 1 degrees of freedom, p = 0.59) or Jadad score at least 3 (χ^2^= 8.11, 4 degrees of freedom, p = 0.09) (Table [3](#T3){ref-type="table"}).
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###### 

Sensitivity-analysis of the effect of corticosteroid prophylaxis of post-ERCP pancreatitis in clinical trials

  **Method**   **Patients**                    **Pooled OR (95% CI)**   **p**
  ------------ ------------------------------- ------------------------ -------
               **PEP**                                                  
                                                                        
  A            2632                            1.13 (0.89, 1.44)        0.32
  B            2328                            1.20 (0.93, 1.55)        0.17
  C            2247                            1.10 (0.85, 1.43)        0.47
  D            2448                            1.13 (0.88, 1.46)        0.34
                                                                        
               **Severe PEP**                                           
                                                                        
  A            2257                            1.61 (0.74, 3.52)        0.23
  B            2073                            1.80 (0.68, 4.72)        0.23
  C            1872                            1.35 (0.47, 3.91)        0.58
  D            2073                            1.80 (0.68, 4.72)        0.23
                                                                        
               **Post-ERCP hyperamylasemia**                            
                                                                        
  A            412                             0.92 (0.57, 1.48)        0.73
  B            228                             0.87 (0.52, 1.46)        0.60
  C            228                             0.87 (0.52, 1.46)        0.60
  D            228                             0.87 (0.52, 1.46)        0.60

A: all included trials \[18--24\]

B: we excluded the trials that the allocation concealment was inadequate or unclear \[18, 24\]

C: we excluded the trials that the blindness was unadopted \[18, 21\]

D: we excluded the trials which published in the form of abstract \[18\]

Severe PEP was reported in five trials \[[@B18],[@B20]-[@B23]\]. These five trials included 2257 patients with 26 patients suffering from severe PEP (16 (1.4%) in corticosteroid treatment group and 10 (0.9%) in control group). The Q test of heterogeneity between studies was not significant (χ^2^= 1.34, 3 degree of freedom, p = 0.72). The meta-analysis did not indicate association between corticosteroid use and reduction of severe PEP \[IV fixed-effect pooled OR 1.61 (95 percent CI 0.74 to 3.52); p = 0.23\] (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). When studies were stratified by setting, there was no significant reduction in severe PEP in either single centre studies (IV fixed-effect pooled OR 1.99 (95 percent CI 0.70 to 5.67); p = 0.20) or multicentre studies (IV fixed-effect pooled OR 1.21 (95 percent CI 0.37 to 4.00); p = 0.75) (Table [3](#T3){ref-type="table"}). There was no significant heterogeneity in single centre studies (χ^2^= 1.12, 2 degrees of freedom, p = 0.57). Only one multicenter study reported severe PEP, so the result of heterogeneity was unavailable. When stratified by Jadad score, there was no significant reduction in severe PEP in Jadad score at 2 or less (IV fixed-effect pooled OR = 1.98 \[(95 percent CI 0.62 to 6.34); p = 0.25) or Jadad score at least 3 (IV fixed-effect pooled OR = 1.35 \[(95 percent CI 0.47 to 3.91); p = 0.58). There was no significant heterogeneity in either Jadad score at 2 or less (χ^2^= 1.12, 1 degrees of freedom, p = 0.29) or Jadad score at least 3 (χ^2^= 0.14, 1 degrees of freedom, p = 0.71) (Table [3](#T3){ref-type="table"}).

###### 

Subgroup analysis of the effect of corticosteroid prophylaxis of post-ERCP pancreatitis in clinical trials

                                                                                     **Heterogeneity**        
  ---------------- ------------------------------- ------------------- ------ ------ ------------------- ---- ------
                   **PEP**                                                                                    
                                                                                                              
  Jadad score                                                                                                 
   ≥ 3             2247                            1.10 (0.85, 1.43)   0.72   0.47   8.11                4    0.09
   ≤ 2             385                             1.31 (0.70, 2.46)   0.85   0.39   0.28                1    0.59
  Setting                                                                                                     
   Single centre   1034                            1.04 (0.66, 1.64)   0.16   0.87   4.75                3    0.19
   Multicentre     1598                            1.17 (0.88, 1.56)   1.07   0.29   3.84                2    0.15
                                                                                                              
                   **Severe PEP**                                                                             
                                                                                                              
  Jadad score                                                                                                 
   ≥ 3             1872                            1.35 (0.47, 3.91)   0.55   0.58   0.14                1    0.71
   ≤ 2             385                             1.98 (0.62, 6.34)   1.14   0.25   1.12                1    0.29
  Setting                                                                                                     
   Single centre   914                             1.99 (0.70, 5.67)   1.28   0.20   1.12                2    0.57
   Multicentre     1343                            1.21 (0.37, 4.00)   0.32   0.75   NA                  NA   NA
                                                                                                              
                   **Post-ERCP hyperamylasemia**                                                              
                                                                                                              
  Jadad score                                                                                                 
   ≥ 3             228                             0.87 (0.52, 1.46)   0.53   0.60   NA                  NA   NA
   ≤ 2             184                             1.24 (0.37, 4.22)   0.35   0.73   NA                  NA   NA
  Setting                                                                                                     
   Single centre   184                             1.24 (0.37, 4.22)   0.35   0.73   NA                  NA   NA
   Multicentre     228                             0.87 (0.52, 1.46)   0.53   0.60   NA                  NA   NA

NA = not applicable

In addition, case-fatality ratio of PEP in these trials was extracted with report of case-fatality ratio in three trials \[[@B20]-[@B22]\]. The three trials included 958 patients but with zero death in corticosteroid group and in placebo group. So, further evaluation of case-fatality ratio of corticosteroid in prophylaxis of PEP is required in the future.

Secondary outcome
-----------------

Both post-ERCP hyperamylasemia and abdominal pain were considered as secondary outcome in the report. For post-ERCP hyperamylasemia, data were derived from two RCTs \[[@B18],[@B22]\]. These trials included 412 patients with 126 patients suffering from post-ERCP hyperamylasemia. Among these patients, 61 (29.9%) patients were treated with corticosteroid and 65 (31.3%) patients with placebo. The Q test of heterogeneity of effect sizes was not significant (χ^2^= 0.28, 1 degree of freedom, p = 0.60). Although the post-ERCP hyperamylasemia was noted in 29.9% of patients with corticosteroid and 31.3% of control patients, the results of the meta-analysis indicated no significant association between the use of corticosteroid and reduction of post-ERCP hyperamylasemia \[IV fixed-effect pooled OR 0.92 (95 percent CI 0.57 to 1.48); p = 0.73\] (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). The subgroup analysis of post-ERCP hyperamylasemia was shown in Table [3](#T3){ref-type="table"}.

We were unable to identify any data on post-ERCP abdominal pain in these trials.

Sensitivity-analysis
--------------------

Three different methods were employed to perform sensitivity-analysis of these trials. First, we excluded the trials that allocation concealment was inadequate or unclear \[[@B18],[@B24]\]. Second, we excluded the trials that blindness was not adopted \[[@B18],[@B21]\]. Third, we excluded the trials which published in abstract \[[@B18]\]. As shown in Table [2](#T2){ref-type="table"}, the overall estimates were virtually identical and the confidence intervals were similar between the sensitivity-analysis and the meta-analysis.

Publication bias
----------------

Publication bias was assessed for all pooled ORs with confidence intervals using Begg\'s test \[[@B29],[@B30]\]. This is a scatter plot with the treatment effects estimated from individual studies on horizontal axis (OR) and the standard error of the estimate on vertical axis (S.E \[log OR\]). In the Figure [3](#F3){ref-type="fig"}, all studies were laid within the 95% CI and were uniformly distributed around the vertical axis, indicating no publication bias (Begg\'s test showed that the p value was 0.133).

![A funnel plot to explore publication bias.](1471-230X-8-6-3){#F3}

Adverse effect
--------------

Adverse effects of corticosteroid were evaluated in current study. We found that three reports indicated different adverse effects of corticosteroid. In one report \[[@B20]\], there are 22 patients with adverse effects. 9 patients were in corticosteroid group and thirteen patients in placebo group. Patients in corticosteroid group had hemorrhage in four cases, cholangitis in three cases and acute cholecystis in two cases. The thirteen patients in the placebo group had the similar adverse events: hemorrhage in six, cholangitis in three, acute cholecystis in four cases. In another report from United States \[[@B19]\], common symptoms such as abdominal pain, vomiting, and fever or chills were reported in both groups with no significant difference between corticosteroid treatment and placebo groups. It was reported by Sherman et al. \[[@B23]\] that the commonest adverse effects in corticosteroid group (i.e., nausea, emesis, sweating, and rash) were also observed with similar frequency in placebo group (5.23% vs. 3.39%, corticosteroid and placebo groups respectively; p = 0.14). Therefore, it was concluded that there was no significant correlation between the use of corticosteroid and adverse effects.

Discussion
==========

Acute pancreatitis is the most frequent and serious complication of ERCP and affords ample opportunity to evaluate potential prophylactic therapy prior to pancreatic injury. There were several attempts intended to find therapeutic agents to prevent post-ERCP pancreatitis. These agents include calcitonin, aprotonin, glucogan, somatostatin, corticosteroid and gabexate mesilate \[[@B5]-[@B12],[@B21]-[@B24],[@B31]-[@B33]\]. Corticosteroid was proposed to use as prophylactic agent for ERCP due to its anti-inflammatory property and autodigestion theory of post-ERCP pancreatitis. Since the report of Dr. Weiner\'s retrospective study of therapeutic use of corticosteroid prior to ERCP procedure, several prospective randomized clinical trials have been conducted. Only few studies indicated a beneficial effect of corticosteroid on prevention of post-ERCP pancreatitis while most clinical trials did not recommend prophylactic use of corticosteroid during ERCP procedure. Moreover, some clinical trials have to be terminated after mid-term evaluation due to increase in incidence of pancreatitis in corticosteroid group compared to that of control group \[[@B22],[@B23]\]. The warrant is due to the report that corticosteroid induced pancreatitis in susceptible patients when administered chronically for non-pancreatic diseases. However, proof of this causal relationship is limited \[[@B34]-[@B36]\]. On the other hand, it has been reported that corticosteroid successfully treat acute pancreatitis \[[@B37]\].

The first study of corticosteroid use in ERCP was conducted in United States in 1995 and the study involved in patients with oral or intravenous corticosteroid in patients with iodine-sensitivity to reduce incidence of PEP \[[@B17]\]. In this report, it was found that corticosteroid was able to reduce pancreatitis after ERCP as compared to the placebo (the occurrences of PEP were 4.6% versus 7.4% respectively). The encouraging results of the retrospective survey of Weiner et al. \[[@B17]\] led to the increasing interest in corticosteroid as a promisable pharmacologic agent for prophylactic prevention of PEP. However, except the study of Kwanngern et al. \[[@B24]\] in 2005, all others studies revealed a negative conclusion of prophylactic use of corticosteroid for ERCP \[[@B18]-[@B23]\]. Therefore, a meta-analysis is needed to evaluate publication bias and conclusion of the results.

Current study collected seven RCTs \[[@B18]-[@B24]\], which were published in the world with different languages. The effectiveness and safety of corticosteroid in the prophylaxis of post-ERCP pancreatitis were evaluated. The meta-analysis showed that occurrences of PEP \[OR = 1.13, 95%CI (0.89\~1.44), p = 0.32\], severe PEP \[OR = 1.61, 95%CI (0.74\~3.52), p = 0.23\], and post-ERCP hyperamylasemia \[OR = 0.92, 95%CI (0.57\~1.48), p = 0.73\] did not correlate with the prophylactic use of corticosteroid. The results of meta-analysis indicated that corticosteroid could not prevent pancreatic injury after ERCP. Moreover, a trend toward higher rates of pancreatitis in corticosteroid treated group suggested that administration of corticosteroid might be hazardous. Furthermore, there was no association between the prophylactic use of corticosteroid and adverse effects although it was reported in three RCTs \[[@B19],[@B20],[@B23]\]. The quality of these RCTs was examined according to the Jadad score \[[@B25]\], and it was found that the results of meta-analysis were consistent with the sensitivity-analysis. Therefore, there was no publication bias in these RCTs.

However, what could be the difference among these RCTs and conclusions? Meta-analysis of these RCTs indicated that there were differences in experimental design (retrospective vs. prospective), forms of corticosteroid (hydrocortisone vs. methylprednisolone or prednisone), doses of corticosteroid (80 mg to 125 mg), routes of administration (oral administration vs. intravenous injection) and time of administration (immediate vs. 15, 3 or 1 hour before ERCP). Retrospective study could be different from prospective study due to patient recruitment and treatment schedule. In addition, the prospective study indicating positive recommendation of corticosteroid application in ERCP had different dose and schedule of corticosteroid (100 mg hydrocortisone intravenously one hour before ERCP) \[[@B24]\] than other RCTs that concluded negative result of corticosteroid use in ERCP (either 120 mg or 100 mg intravenously immediately before ERCP or 40 mg orally 15 and 3 hours before ERCP) \[[@B18]-[@B23]\]. Therefore, further studies with the standard administration of corticosteroids in ERCP are needed to provide solid evidence regarding its effectiveness in the prevention of post-ERCP pancreatitis.

Conclusion
==========

In conclusion, the present study shows no statistically significant benefit of prophylactic corticosteroid use for prevention of PEP. Therefore, the use of corticosteroids in the prophylaxis of PEP is not routinely recommended.
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